Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
An open-label, multi-dose clinical trial design was used to investigate the combination of
MB07133 injection combined with Sintilimab in the treatment of primary liver cancer in phase
I/IIa studies, including two phases of dose escalation and dose expansion，in order to
evaluate the safety and efficacy of MB07133 injection combined with Sintilimab.